Table 3

Drugs with significant enrichment to diurnal signature in the Connectivity Map

rank

drug

mean

n

p-value


1

sirolimus

0.68

10

0

2

LY-294002

0.54

17

0

3

wortmannin

0.62

8

0.0001

4

trichostatin A

0.48

12

0.0012

5

resveratrol

0.61

5

0.0026

6

5182598

-0.78

2

0.0043

7

estradiol

-0.39

10

0.0079

8

iloprost

-0.71

3

0.0105

9

tacrolimus

-0.56

3

0.0153

10

arachidonyltrifluoromethane

-0.75

2

0.02

11

deferoxamine

0.49

3

0.0292

12

fludrocortisone

-0.60

2

0.0429

13

quercetin

-0.53

2

0.0607

14

TTNPB

-0.57

2

0.0645

15

vorinostat

0.53

2

0.0734

16

fulvestrant

0.39

7

0.0858

17

raloxifene

-0.15

3

0.0876

18

rottlerin

0.43

3

0.0945


The drugs with significant connectivity to the diurnal signature are ranked in the order of significance of the connectivity score as judged by the permutation p-value (column labeled "p-value"). Significance cut-off was set at pvalue = 0.1. The permutation p-value estimates the likelihood that the enrichment of a given set of post-dose gene expression changes (instances) by a given drug, relative to all available post-dose changes in the CMAP database (for all drugs) would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the post-dose changes by the given drug; N: the number of instances of a given drug in CMAP database[23].

Loboda et al. BMC Medical Genomics 2009 2:7   doi:10.1186/1755-8794-2-7

Open Data